Qiagen (QGEN) Stock Price, News & Analysis

Company Overview

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Key Stats

• Today's Range: $38.80 to $39.59
• 50-Day Range: $38.56 to $46.22
• 52-Week Range: $38.49 to $49.30
• Volume: 1.26 million shs
• Average Volume: 1.29 million shs
• Market Capitalization: $8.77 billion
• P/E Ratio: 110.03
• Dividend Yield: N/A
• Price Target: $47.71
• Consensus Rating: Hold

Qiagen Stock Analysis - MarketRank™

Qiagen scored higher than 89% of companies evaluated by MarketBeat, and ranked 110th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Qiagen has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 3 buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Qiagen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 8.85%

Earnings Growth

Earnings for Qiagen are expected to grow by 8.85% in the coming year, from $2.26 to $2.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Qiagen is 110.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Qiagen is 110.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.46.

Price to Earnings Growth Ratio

Qiagen has a PEG Ratio of 2.43. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Qiagen has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.18% of the float of Qiagen has been sold short.

Short Interest Ratio / Days to Cover

Qiagen has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Qiagen has recently decreased by 16.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Qiagen does not currently pay a dividend.

Dividend Growth

Qiagen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

1.18% of the float of Qiagen has been sold short.

Short Interest Ratio / Days to Cover

Qiagen has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Qiagen has recently decreased by 16.12%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.37

News Sentiment

Qiagen has a news sentiment score of -0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Qiagen this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for QGEN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Qiagen to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Qiagen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.00% of the stock of Qiagen is held by insiders.

Percentage Held by Institutions

70.00% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

QGEN Stock Analysis - Frequently Asked Questions

How have QGEN shares performed this year?

Qiagen's stock was trading at $43.2931 at the start of the year. Since then, QGEN shares have decreased by 8.7% and is now trading at $39.5150.
View the best growth stocks for 2025 here.

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) posted its quarterly earnings results on Wednesday, February, 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a trailing twelve-month return on equity of 13.92%.

When did Qiagen's stock split?

Qiagen shares split before market open on Wednesday, January 29th 2025. The 36-35 split was announced on Wednesday, January 22nd 2025. The newly created shares were issued to shareholders after the closing bell on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the split would have 103 shares after the split.

Who are Qiagen's major shareholders?

Qiagen's top institutional shareholders include Groupama Asset Managment (14.34%), Massachusetts Financial Services Co. MA (11.41%), Wellington Management Group LLP (9.82%) and Vanguard Group Inc. (4.00%).

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Qiagen investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and PayPal (PYPL).

Company Calendar

• Last Earnings: 2/05/2025
• Today: 2/21/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:QGEN
• CUSIP: N/A
• CIK: 1015820
• Web: www.qiagen.com
• Phone: (177) 355-6600
• Fax: 31-77-355-6658
• Employees: 5,967
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $47.71
• High Stock Price Target: $52.50
• Low Stock Price Target: $42.00
• Potential Upside/Downside: +20.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.3591
• Trailing P/E Ratio: 110.03
• Forward P/E Ratio: 17.48
• P/E Growth: 2.43
• Net Income: $83.59 million
• Net Margins: 4.23%
• Pretax Margin: 6.12%
• Return on Equity: 13.92%
• Return on Assets: 8.40%

Debt

• Debt-to-Equity Ratio: 0.38
• Current Ratio: 3.61
• Quick Ratio: 3.09

Sales & Book Value

• Annual Sales: $1.98 billion
• Price / Sales: 4.43
• Cash Flow: $3.24 per share
• Price / Cash Flow: 12.21
• Book Value: $16.08 per share
• Price / Book: 2.46

Miscellaneous

• Outstanding Shares: 221,860,000
• Free Float: 201,892,000
• Market Cap: $8.77 billion
• Optionable: Optionable
• Beta: 0.36